Peter D Tonge
Overview
Explore the profile of Peter D Tonge including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
665
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lipsitz Y, Tonge P, Zandstra P
Biotechnol Bioeng
. 2018 Apr;
115(8):2061-2066.
PMID: 29679475
Heterogeneity in pluripotent stem cell (PSC) aggregation leads to variability in mass transfer and signaling gradients between aggregates, which results in heterogeneous differentiation and therefore variability in product quality and...
2.
Agnihotri S, Suppiah S, Tonge P, Jalali S, Danesh A, Bruce J, et al.
Nat Commun
. 2017 Aug;
8(1):186.
PMID: 28775249
Cranial radiotherapy improves survival of the most common childhood cancers, including brain tumors and leukemia. Unfortunately, long-term survivors are faced with consequences of secondary neoplasia, including radiation-induced meningiomas (RIMs). We...
3.
Agnihotri S, Jalali S, Wilson M, Danesh A, Li M, Klironomos G, et al.
Nat Genet
. 2016 Oct;
48(11):1339-1348.
PMID: 27723760
Schwannomas are common peripheral nerve sheath tumors that can cause debilitating morbidities. We performed an integrative analysis to determine genomic aberrations common to sporadic schwannomas. Exome sequence analysis with validation...
4.
Vartanian A, Agnihotri S, Wilson M, Burrell K, Tonge P, Alamsahebpour A, et al.
Oncotarget
. 2016 Sep;
7(43):69518-69535.
PMID: 27588472
First-line cancer therapies such as alkylating agents and radiation have limited survival benefits for Glioblastoma (GBM) patients. Current research strongly supports the notion that inhibition of aberrant tumor metabolism holds...
5.
Tonge P, Corso A, Monetti C, Hussein S, Puri M, Michael I, et al.
Nature
. 2015 Jun;
523(7562):626.
PMID: 26083751
No abstract available.
6.
Hussein S, Puri M, Tonge P, Benevento M, Corso A, Clancy J, et al.
Nature
. 2015 Jun;
523(7562):626.
PMID: 26083747
No abstract available.
7.
Benevento M, Tonge P, Puri M, Nagy A, Heck A, Munoz J
Proteomics
. 2015 Jun;
15(18):3219-31.
PMID: 26080932
Cellular reprogramming remodels the gene expression program by re-setting the epigenome of somatic cells into an embryonic-like pluripotent state. Post-translational modifications of histones play an important role in this process....
8.
Shakiba N, White C, Lipsitz Y, Yachie-Kinoshita A, Tonge P, Hussein S, et al.
Nat Commun
. 2015 Jun;
6:7329.
PMID: 26076835
Reprogramming is a dynamic process that can result in multiple pluripotent cell types emerging from divergent paths. Cell surface protein expression is a particularly desirable tool to categorize reprogramming and...
9.
Hussein S, Puri M, Tonge P, Benevento M, Corso A, Clancy J, et al.
Nature
. 2014 Dec;
516(7530):198-206.
PMID: 25503233
Somatic cell reprogramming to a pluripotent state continues to challenge many of our assumptions about cellular specification, and despite major efforts, we lack a complete molecular characterization of the reprograming...
10.
Tonge P, Corso A, Monetti C, Hussein S, Puri M, Michael I, et al.
Nature
. 2014 Dec;
516(7530):192-7.
PMID: 25503232
Pluripotency is defined by the ability of a cell to differentiate to the derivatives of all the three embryonic germ layers: ectoderm, mesoderm and endoderm. Pluripotent cells can be captured...